Radiation Toxicity Treatment Market value of US$ 5.5 Billion by the end of forecast period (2022 – 2029) and further experience a major upturn post 2029

[194 Pages Report] The rise in installation of radiation therapy machines to treat a wide range of cancers further uplifts the probability of radiation toxicity in cancer patients. Future Market Insights (FMI), in its new study on the global radiation toxicity treatment market, foresees that the market will reach the value of US$ 5.5 Bn by the end of forecast period (2022 – 2029) and further experience a major upturn post 2029.

Installed base of internal radiation therapy machines has tremendously increased over the past decade. Improving reimbursement scenario and favorable government policy framework in the field of cancer care are adding to the accessibility of radiation therapy, thereby favoring the growth of radiation toxicity treatment market.

The study suggests that notable players in Asia Pacific will continue to invest heavily in the development of new radiation therapies, in line with the increasing cancer prevalence and improving rate of diagnosis in the region.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-10724

Market Outlook:

Rising incidence of radiation toxicity in healthcare and chemicals industries continues to push the demand for effective treatment. Another important factor complementing the market growth includes recent FDA approvals to multiple orphan drugs that are proven to effectively increase the survival rate in adult and paediatric patients who are suffering from radiation sickness. These application areas continue to create growth opportunities in the radiation toxicity treatment market.

Key Takeaways – Radiation Toxicity Treatment Market Study

• Increasing adoption of colony stimulating factors such as Neulasta from Amgen will account for more than 75% of revenue share in the radiation toxicity treatment market through 2029 end.
• Attributed to high incidences of radiation toxicity due to emission of gamma radiation from positron emission tomography (PET) and single-photon emission computed tomography (SPECT) scanners installed at hospitals and diagnostic centers, non-ionizing radiation is also set to offer lucrative opportunity to market participants.
• North America continues to lead its way in the radiation toxicity treatment market, while South Asia is foreseen to grow at a significant rate in the near future.

Who Is Winning?

Some of the key players operating in the radiation toxicity treatment market include Amgen Inc., Partner Therapeutics, Mylan N.V., and Novartis AG. Leading players of the radiation toxicity treatment market are focusing on acquiring smaller companies to enhance their product portfolio and improve regional market positioning.

For instance, Siegfried Group announced the acquisition of drug product manufacturing facility together with all related employees and contracts from Arena Pharmaceuticals GmbH in Zofingen, Switzerland. Also, in 2018, Partner Therapeutics (PTx) acquired global rights to develop, manufacture, and commercialize Leukine (sargramostim) from Sanofi.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-10724

Know More About the Report

Radiation toxicity treatment market, a new study from future market insights, opines on the evolution of the radiation toxicity treatment market from 2014 – 2021 and presents demand projections from 2022 – 2029 on the basis of; product type (colony stimulating factors, potassium iodide, prussian blue, diethylenetriamine pentaacetic acid, and others), indication (acute radiation syndrome and chronic radiation syndrome), radiation type (ionizing radiation and non-ionizing radiation) and end user (hospitals and research & academic institutes) across seven prominent regions.

Radiation toxicity treatment Market by Category

By Product :

• Colony Stimulating Factors
• Potassium Iodide
• Prussian Blue
• Diethylenetriamine Pentaacetic Acid
• Others

By Indication :

•  Acute Radiation Syndrome
  • Bone Marrow Syndrome (Hematopoietic)
  • Gastrointestinal Syndrome (GI)
  • Cardiovascular (CV)
• Chronic Radiation Syndrome

By Radiation Type :

• Ionizing Radiation
  • Alpha Radiation
  • Beta Radiation
  • Gamma Radiation
• Non-ionizing Radiation

By End-User :

• Hospitals
  • Government Hospitals
  • Private Hospitals
• Research & Academic Institutes
  • Government Research and Academic Institutes
  • Private Research and Academic Institutes

By Region :

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa (MEA)

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact:
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com/